Tags

Type your tag names separated by a space and hit enter

Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Am J Cardiol. 2010 May 15; 105(10):1409-12.AJ

Abstract

The present post hoc analysis of data from the COMBination of prescription Omega-3 with Simvastatin (COMBOS) study investigated the predictors of the low-density lipoprotein (LDL) cholesterol response to prescription omega-3 acid ethyl ester (P-OM3) therapy in men and women with high (200 to 499 mg/dl) triglycerides during diet plus simvastatin therapy. Subjects (n = 256 randomized) received double-blind P-OM3 4 g/day or placebo for 8 weeks combined with diet and open-label simvastatin 40 mg/day. The percentage of changes from baseline (with diet plus simvastatin) in lipids was evaluated by tertiles of baseline LDL cholesterol and triglyceride concentrations. The baseline LDL cholesterol tertile was a significant predictor of the LDL cholesterol response (p = 0.022 for the treatment by baseline tertile interaction). The median LDL cholesterol response in the P-OM3 group was +9.5% (first tertile, <80.4 mg/dl), -0.9% (second tertile), and -6.4% (third tertile, > or =99.0 mg/dl). Non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride responses did not vary significantly by baseline LDL cholesterol tertile. The reductions in very-low-density lipoprotein cholesterol concentrations were greater than the increases in LDL cholesterol, where present, resulting in a net decrease in the concentration of cholesterol carried by atherogenic particles (non-high-density lipoprotein cholesterol) in all baseline LDL cholesterol tertiles. In conclusion, these results suggest that the increase in LDL cholesterol that occurred with the addition of P-OM3 to simvastatin therapy in subjects with mixed dyslipidemia was confined predominantly to those with low LDL cholesterol levels while receiving simvastatin monotherapy.

Authors+Show Affiliations

Provident Clinical Research, Glen Ellyn, Illinois, USA. kmaki@providentcrc.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20451686

Citation

Maki, Kevin C., et al. "Baseline Lipoprotein Lipids and Low-density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy." The American Journal of Cardiology, vol. 105, no. 10, 2010, pp. 1409-12.
Maki KC, Dicklin MR, Davidson MH, et al. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010;105(10):1409-12.
Maki, K. C., Dicklin, M. R., Davidson, M. H., Doyle, R. T., & Ballantyne, C. M. (2010). Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. The American Journal of Cardiology, 105(10), 1409-12. https://doi.org/10.1016/j.amjcard.2009.12.063
Maki KC, et al. Baseline Lipoprotein Lipids and Low-density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy. Am J Cardiol. 2010 May 15;105(10):1409-12. PubMed PMID: 20451686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. AU - Maki,Kevin C, AU - Dicklin,Mary R, AU - Davidson,Michael H, AU - Doyle,Ralph T, AU - Ballantyne,Christie M, AU - ,, Y1 - 2010/03/30/ PY - 2009/10/20/received PY - 2009/12/22/revised PY - 2009/12/22/accepted PY - 2010/5/11/entrez PY - 2010/5/11/pubmed PY - 2010/6/2/medline SP - 1409 EP - 12 JF - The American journal of cardiology JO - Am J Cardiol VL - 105 IS - 10 N2 - The present post hoc analysis of data from the COMBination of prescription Omega-3 with Simvastatin (COMBOS) study investigated the predictors of the low-density lipoprotein (LDL) cholesterol response to prescription omega-3 acid ethyl ester (P-OM3) therapy in men and women with high (200 to 499 mg/dl) triglycerides during diet plus simvastatin therapy. Subjects (n = 256 randomized) received double-blind P-OM3 4 g/day or placebo for 8 weeks combined with diet and open-label simvastatin 40 mg/day. The percentage of changes from baseline (with diet plus simvastatin) in lipids was evaluated by tertiles of baseline LDL cholesterol and triglyceride concentrations. The baseline LDL cholesterol tertile was a significant predictor of the LDL cholesterol response (p = 0.022 for the treatment by baseline tertile interaction). The median LDL cholesterol response in the P-OM3 group was +9.5% (first tertile, <80.4 mg/dl), -0.9% (second tertile), and -6.4% (third tertile, > or =99.0 mg/dl). Non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride responses did not vary significantly by baseline LDL cholesterol tertile. The reductions in very-low-density lipoprotein cholesterol concentrations were greater than the increases in LDL cholesterol, where present, resulting in a net decrease in the concentration of cholesterol carried by atherogenic particles (non-high-density lipoprotein cholesterol) in all baseline LDL cholesterol tertiles. In conclusion, these results suggest that the increase in LDL cholesterol that occurred with the addition of P-OM3 to simvastatin therapy in subjects with mixed dyslipidemia was confined predominantly to those with low LDL cholesterol levels while receiving simvastatin monotherapy. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/20451686/Baseline_lipoprotein_lipids_and_low_density_lipoprotein_cholesterol_response_to_prescription_omega_3_acid_ethyl_ester_added_to_Simvastatin_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(10)00072-X DB - PRIME DP - Unbound Medicine ER -